Xin Lang Cai Jing·2025-10-14 01:56Core Viewpoint - Zhaoyan New Drug's stock price has shown significant volatility, with a year-to-date increase of 100.36% but a recent decline in the last five trading days by 5.81% [1] Group 1: Stock Performance - As of October 14, Zhaoyan New Drug's stock price was 33.26 CNY per share, with a market capitalization of 24.928 billion CNY [1] - The stock has experienced a 27.38% increase over the past 60 days, while it has decreased by 4.01% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent occurrence on September 15 [1] Group 2: Financial Performance - For the first half of 2025, Zhaoyan New Drug reported a revenue of 669 million CNY, a year-on-year decrease of 21.28%, while the net profit attributable to shareholders was 60.932 million CNY, reflecting a year-on-year increase of 135.90% [2] - Cumulative cash dividends since the company's A-share listing amount to 703 million CNY, with 356 million CNY distributed over the past three years [3] Group 3: Shareholder Structure - As of June 30, 2025, the number of shareholders increased to 61,200, a rise of 25.59% compared to the previous period [2] - The top circulating shareholder, Huabao Zhongzheng Medical ETF, holds 14.6531 million shares, an increase of 2.2669 million shares from the previous period [3] - Hong Kong Central Clearing Limited, ranked as the eighth largest circulating shareholder, reduced its holdings by 9.4387 million shares to 8.2811 million shares [3]